

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Aberdare GP II, L.L.C.</u> (Last) (First) (Middle) ONE EMBARCADERO CENTER SUITE 4000 (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/14/2007	3. Issuer Name and Ticker or Trading Symbol <u>EnteroMedics Inc [ETRM]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are held	000	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	21,607	(1)	D ⁽²⁾⁽³⁾	
Series B Preferred Stock	(1)	(1)	Common Stock	952,972	(1)	D ⁽²⁾⁽⁴⁾	
Series B Preferred Stock	(1)	(1)	Common Stock	38,853	(1)	I ⁽²⁾	Paul Klingenstein
Series C Preferred Stock	(1)	(1)	Common Stock	237,254	(1)	D ⁽²⁾⁽⁵⁾	
Series C Preferred Stock	(1)	(1)	Common Stock	5,327	(1)	D ⁽²⁾⁽³⁾	
Series C Preferred Stock	(1)	(1)	Common Stock	19,238	(1)	I ⁽²⁾	Paul Klingenstein
Series C Preferred Stock	(1)	(1)	Common Stock	235,086	(1)	D ⁽²⁾⁽⁴⁾	
Common Stock Warrant	(6)	12/12/2010	Common Stock	937	0.46	D ⁽²⁾⁽³⁾	
Common Stock Warrant	(6)	12/12/2010	Common Stock	41,293	0.46	D ⁽²⁾⁽⁴⁾	
Common Stock Warrant	(6)	12/12/2010	Common Stock	1,684	0.46	I ⁽²⁾	Paul Klingenstein

1. Name and Address of Reporting Person*
Aberdare GP II, L.L.C.
 (Last) (First) (Middle)
 ONE EMBARCADERO CENTER
 SUITE 4000
 (Street)
 SAN FRANCISCO CA 94111
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Aberdare Ventures II, L.P.
 (Last) (First) (Middle)
 ONE EMBARCADERO CENTER

SUITE 4000

(Street)

SAN FRANCISCO CA 94111

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Aberdare Ventures II (Bermuda), L.P.

(Last)

(First)

(Middle)

ONE EMBARCADERO CENTER

SUITE 4000

(Street)

SAN FRANCISCO CA 94111

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

ABERDARE II ANNEX FUND L P

(Last)

(First)

(Middle)

ONE EMBARCADERO CENTER

SUITE 4000

(Street)

SAN FRANCISCO CA 94111

(City)

(State)

(Zip)

Explanation of Responses:

1. The convertible preferred stock will automatically convert one-to-one into common stock upon completion of the initial public offering.
2. Paul Klingenstein, a director of EnteroMedics Inc., is a managing partner and Aberdare GP II, LLC is the general partner of each of Aberdare Ventures II, L.P., Aberdare Ventures II (Bermuda), L.P. and Aberdare II Annex Fund, L.P.
3. Represents shares held by Aberdare Ventures II (Bermuda), L.P.
4. Represents shares held by Aberdare Ventures II, L.P.
5. Represents shares held by Aberdare II Annex Fund, L.P.
6. Immediately exercisable.

Remarks:

Signed by Paul Klingenstein, as Managing Partner, for and on behalf of Aberdare Ventures GP II, LLC, Aberdare Ventures II, L.P., Aberdare Ventures II (Bermuda), L.P. and Aberdare II Annex Fund, L.P.

/s/ Paul Klingenstein,
Managing Partner

11/13/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.